Astellas Pharma Inc. ALPMF
17.32 USD +0.77 (+4.65%)
Regular-session close
16.55 Day range 16.55
11.40 52-week range 18.03
- YTD
- +31.51%
- 1 year
- +45.18%
News
benzinga.com Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer European committee backs Merck's Keytruda + Padcev combo for bladder cancer after Phase 3 trial slashes risk of recurrence by 47%.
seekingalpha.com Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors The portfolio outperformed the MSCI EAFE benchmark in the second quarter of 2026. Contributors include Infineon Technologies, Tokyo Electron and Recruit Holdings. Detractors include Murata…
seekingalpha.com Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
seekingalpha.com Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
seekingalpha.com Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at…
prnewswire.com Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer - Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir…
reuters.com India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma over the bladder disorder drug Mirabegron, allowing it to continue selling the product…
seekingalpha.com Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
benzinga.com Why Is Monte Rosa Stock Trading Higher Today? Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi in advanced prostate cancer patients.
benzinga.com Why Is Taysha Gene Therapies Stock Falling Friday? Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.
seekingalpha.com Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2024 Earnings Conference Call April 25, 2025 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Naoki Okamura - Representative…
seekingalpha.com Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward Astellas Pharma Inc. has a diverse pipeline with significant growth in oncology, driven by new approvals for drugs like zolbetuximab. Despite recent stock declines, ALPMF's revenue and core profits…
seekingalpha.com Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2024 Earnings Conference Call February 4, 2025 2:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Atsushi Kitamura - Chief…
seekingalpha.com Astellas Pharma Inc. (ALPMF) Q1 2024 Earnings Call Transcript Astellas Pharma Inc. (OTCPK:ALPMF) Q1 2024 Earnings Conference Call August 1, 2024 3:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IRO Tadaaki Taniguchi - CMO Claus Zieler…
seekingalpha.com Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2023 Results Conference Call April 25, 2024 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and Investor Relations Officer Naoki Okamura -…
prnewswire.com China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer - Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy- - If approved, enfortumab…
seekingalpha.com Astellas Pharma Inc. (ALPMF) Q3 2023 Earnings Call Transcript Astellas Pharma Inc. (ALPMF) Q3 2023 Earnings Call Transcript
prnewswire.com EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children - Astellas contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium - TOKYO , Dec. 17, 2023 /PRNewswire/ -- Astellas…
seekingalpha.com Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call November 1, 2023 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy & Relations Atsushi Kitamura - Chief…
seekingalpha.com Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call August 1, 2023 4:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura -…
prnewswire.com Astellas Completes Acquisition of Iveric Bio TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the…
marketwatch.com You can't rely on indexes to pick international stocks, this 5-star fund manager says. Here are 3 of his top selections. You have probably seen coverage of a renewed interest in Japanese stocks among well-known investors, including Berkshire Hathaway BRK.B, -0.57% CEO Warren Buffett. But Krishna Mohanraj, who runs a…
proactiveinvestors.com Iveric Bio stock surges on Astellas Pharma takeover deal Iveric Bio Inc shares climbed 16% to $38.01 on Monday after the US drugmaker agreed to be acquired by Japan's Astellas Pharma for $40 per share in cash or total consideration of about $5.9 billion.…benzinga.com Stocks That Hit 52-Week Highs On Tuesday
